Skip to main content

Insomnia News (Page 7)

Related terms: Difficulty Sleeping, Dyssomnia, Inability to sleep, Sleeplessness, Wakefulness

Poor Long-Term Sleep Trajectories Tied to Diabetes

TUESDAY, Aug. 13, 2024 – Adults with suboptimal sleep duration trajectories are more likely to develop incident diabetes, according to a study published online June 27 in Diabetologia. Qian Xiao, ...

FDA Approves Quviviq (daridorexant) for the Treatment of Adults with Insomnia

Allschwil, Switzerland – January 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has approved Quviviq (daridorexant) 25 mg and 50 mg for the treatment o...

FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients

December 23, 2019 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-...

FDA Approves Belsomra (suvorexant) for Insomnia

August 13, 2014 – The U.S. Food and Drug Administration today approved Belsomra (suvorexant) tablets for use as needed to treat difficulty in falling and staying asleep (insomnia). Belsomra is an...

FDA Medwatch Alert: Eszopiclone Containing Sleep Aids: Drug Safety Communication - Can Cause Next-Day Impairment

Including Lunesta and generics [Posted 05/15/2014] ISSUE: FDA has notified health professionals and their medical care organizations of a new warning that the insomnia drug Lunesta (eszopiclone)...

FDA Medwatch Alert: Tranquility by Health and Beyond, LLC: Recall - Undeclared Drug Ingredient

ISSUE: Health and Beyond LLC is voluntarily recalling quantity lots of product Tranquility. The products have been found to contain a trace of Doxepin which is a pharmaceutical for sleep and...

FDA Medwatch Alert: Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Including Ambien, Ambien CR, Edluar, and Zolpimist  [UPDATE 05/14/2013] Today, the U.S. Food and Drug Administration (FDA) is notifying the public that FDA has approved label changes specifying new ...

FDA Medwatch Alert: Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Including Ambien, Ambien CR, Edluar, and Zolpimist    [Posted 01/10/2013] ISSUE: FDA is notifying the public of new information about zolpidem, a widely prescribed insomnia drug. FDA recommends that ...

FDA Approves Intermezzo for Middle-of-the-Night Waking Followed by Difficulty Returning to Sleep

November 23, 2011 – The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night...

Somaxon Announces FDA Approval of Silenor (doxepin) for the Treatment of Insomnia

SAN DIEGO, CA – March 18, 2010 - Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for t...

FDA Medwatch Alert: Sedative-hypnotic drug products

[Posted 03/14/2007] FDA notified healthcare professionals of its request that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Nightmares, Night Terrors, Sleep Disorders

Related drug support groups

gabapentin, trazodone, clonazepam, mirtazapine, amitriptyline, Ativan, Ambien, lorazepam, melatonin, view more... quetiapine, zolpidem, diphenhydramine, olanzapine, temazepam, Tylenol PM, Lunesta, doxepin, Sleep Aid, valerian, Unisom, 5-HTP, phenobarbital